| P2093 | author name string | Amy Kutschke | |
| | Sushmita D Lahiri | |
| | Richard A Alm | |
| | Kathy McCormack | |
| P2860 | cites work | Structural basis of gate-DNA breakage and resealing by type II topoisomerases | Q27324504 |
| | Oxabicyclooctane-Linked Novel Bacterial Topoisomerase Inhibitors as Broad Spectrum Antibacterial Agents | Q27644560 |
| | Structural basis for gate-DNA recognition and bending by type IIA topoisomerases | Q27649385 |
| | Structural insight into the quinolone-DNA cleavage complex of type IIA topoisomerases | Q27655501 |
| | Type IIA topoisomerase inhibition by a new class of antibacterial agents | Q27663884 |
| | The Structure of DNA-Bound Human Topoisomerase II Alpha: Conformational Mechanisms for Coordinating Inter-Subunit Interactions with DNA Cleavage | Q27670934 |
| | Structure of an 'open' clamp type II topoisomerase-DNA complex provides a mechanism for DNA capture and transport | Q27679776 |
| | Mapping the spectrum of conformational states of the DNA- and C-gates in Bacillus subtilis gyrase | Q27684449 |
| | Novel hydroxyl tricyclics (e.g., GSK966587) as potent inhibitors of bacterial type IIA topoisomerases | Q27685406 |
| | Discovery and characterization of QPT-1, the progenitor of a new class of bacterial topoisomerase inhibitors | Q33339829 |
| | Fluoroquinolone-gyrase-DNA complexes: two modes of drug binding | Q33556083 |
| | Efficacy, Safety, and Tolerability of Gepotidacin (GSK2140944) in the Treatment of Patients with Suspected or Confirmed Gram-Positive Acute Bacterial Skin and Skin Structure Infections | Q33726674 |
| | Challenges of antibacterial discovery | Q33793074 |
| | Current and novel antibiotics against resistant Gram-positive bacteria | Q35026521 |
| | Characterization of the novel DNA gyrase inhibitor AZD0914: low resistance potential and lack of cross-resistance in Neisseria gonorrhoeae. | Q35076809 |
| | All tangled up: how cells direct, manage and exploit topoisomerase function | Q35154537 |
| | In vitro and in vivo activities of PD 0305970 and PD 0326448, new bacterial gyrase/topoisomerase inhibitors with potent antibacterial activities versus multidrug-resistant gram-positive and fastidious organism groups | Q35758905 |
| | Sequential acquisition of norfloxacin and ofloxacin resistance by methicillin-resistant and -susceptible Staphylococcus aureus | Q35899647 |
| | Global fluoroquinolone resistance epidemiology and implictions for clinical use. | Q36337074 |
| | Multidrug-resistant and extensively drug-resistant Gram-negative pathogens: current and emerging therapeutic approaches. | Q36761826 |
| | Topoisomerase IV-quinolone interactions are mediated through a water-metal ion bridge: mechanistic basis of quinolone resistance | Q36783606 |
| | The role of DNA bending in type IIA topoisomerase function | Q36878467 |
| | NBTI 5463 is a novel bacterial type II topoisomerase inhibitor with activity against gram-negative bacteria and in vivo efficacy | Q37713025 |
| | Improving known classes of antibiotics: an optimistic approach for the future | Q38022874 |
| | New antibiotics for bad bugs: where are we? | Q38132217 |
| | Treatment of infections due to resistant Staphylococcus aureus | Q38148512 |
| | Which antibiotic for resistant Gram-positives, and why? | Q38159788 |
| | Activities of trovafloxacin compared with those of other fluoroquinolones against purified topoisomerases and gyrA and grlA mutants of Staphylococcus aureus. | Q39471404 |
| | Quinolone resistance-determining region in the DNA gyrase gyrB gene of Escherichia coli | Q40087129 |
| | Target-based resistance in Pseudomonas aeruginosa and Escherichia coli to NBTI 5463, a novel bacterial type II topoisomerase inhibitor | Q41687386 |
| | Functional determinants of gate-DNA selection and cleavage by bacterial type II topoisomerases | Q41848451 |
| | Hot-spot consensus of fluoroquinolone-mediated DNA cleavage by Gram-negative and Gram-positive type II DNA topoisomerases | Q41859520 |
| | Mechanism of action of the antibiotic NXL101, a novel nonfluoroquinolone inhibitor of bacterial type II topoisomerases | Q41925162 |
| | First case of VRSA identified in Michigan. | Q44108006 |
| | Multi-drug resistant bacteria and antibiotics | Q44838838 |
| | Novel N-linked aminopiperidine inhibitors of bacterial topoisomerase type II with reduced pK(a): antibacterial agents with an improved safety profile | Q46759921 |
| | Design, synthesis, and characterization of novel tetrahydropyran-based bacterial topoisomerase inhibitors with potent anti-gram-positive activity | Q47723849 |
| | Methicillin-resistant Staphylococcus aureus clinical strain with reduced vancomycin susceptibility. | Q55067143 |
| | Evaluation of quinolone resistance-determining region mutations and efflux pump expression in Neisseria meningitidis resistant to fluoroquinolones | Q83416712 |
| | Novel N-linked aminopiperidine inhibitors of bacterial topoisomerase type II: broad-spectrum antibacterial agents with reduced hERG activity | Q85097205 |
| P433 | issue | 9 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | Staphylococcus aureus | Q188121 |
| P304 | page(s) | 5278-5287 | |
| P577 | publication date | 2015-06-15 | |
| P1433 | published in | Antimicrobial Agents and Chemotherapy | Q578004 |
| P1476 | title | Insights into the mechanism of inhibition of novel bacterial topoisomerase inhibitors from characterization of resistant mutants of Staphylococcus aureus | |
| P478 | volume | 59 | |